Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus

J Infect Dis. 1998 Aug;178(2):413-22. doi: 10.1086/515642.

Abstract

The activity of three human immunodeficiency virus (HIV) protease inhibitors was investigated in human primary monocytes/macrophages (M/M) chronically infected by HIV-1. Saquinavir, KNI-272, and ritonavir inhibited the replication of HIV-1 in vitro, with EC50s of approximately 0.5-3.3 microM. However, only partial inhibition was achievable, even at the highest concentrations tested. Also, the activity of these drugs in chronically infected M/M was approximately 7- to 26-fold lower than in acutely infected M/M and approximately 2- to 10-fold lower than in chronically infected H9 lymphocytes. When protease inhibitors were removed from cultures of chronically infected M/M, production of virus rapidly returned to the levels found in untreated M/M. Therefore, relatively high concentrations of protease inhibitors are required to suppress HIV-1 production in chronically infected macrophages, and such cells may be a vulnerable point for the escape of virus in patients taking these drugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Cell Line
  • Cells, Cultured
  • HIV Core Protein p24 / analysis
  • HIV Protease Inhibitors / pharmacology*
  • HIV-1 / drug effects*
  • HIV-1 / isolation & purification
  • HIV-1 / physiology
  • Humans
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / virology*
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / virology*
  • Oligopeptides / pharmacology*
  • Reverse Transcriptase Inhibitors / pharmacology
  • Ritonavir / pharmacology*
  • Saquinavir / pharmacology*
  • Zidovudine / pharmacology

Substances

  • Anti-HIV Agents
  • HIV Core Protein p24
  • HIV Protease Inhibitors
  • Oligopeptides
  • Reverse Transcriptase Inhibitors
  • Zidovudine
  • Saquinavir
  • kynostatin 272
  • Ritonavir